Antibody-drug conjugate · Cytotoxic, directed at integrin beta-6 (ITGB6) · developed by PFIZER
PF-08046876 is an antibody-drug conjugate that binds integrin beta-6 (IB6) on tumor cells and carries a camptothecin analog, AMDCPT, linked by a cleavable glucuronide linker. After internalization and linker cleavage, the released payload inhibits DNA topoisomerase-1, causing cell cycle arrest and apoptosis. It is being studied in solid tumors including bladder, lung, head and neck, esophageal and pancreatic cancers.
Summary written with AI from the sources listed at the end of this page.
Advanced Non-Small Cell Lung CancerAdvanced/Metastatic Solid TumorsBladder CancerCarcinoma, Non Small Cell LungCarcinoma, Squamous Cell of Head and NeckEsophageal AdenocarcinomaEsophageal CancerEsophageal Squamous Cell CarcinomaGastroesophageal Junction AdenocarcinomaHead and Neck CancerPancreatic AdenocarcinomaPancreatic CancerUrothelial Carcinoma
Updated Nov 8, 2026. Something wrong or missing? Report it on the PFE page.
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →